1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

22 May 2023
Admin
News Article

Daiichi Sankyo begins phase 3 trial of mutant strain Covid-19 vaccine, DS-5670 in Japan

Daiichi Sankyo announced that it has administered an mRNA vaccine (DS-5670) against the novel coronavirus infectious disease (Covid-19), which is being developed by Daiichi Sankyo in Japan, to the first subject in a phase 3 clinical trial of a booster vaccination with an Omicron-adapted bivalent vaccine (booster vaccination trial). This booster vaccination trial is a phase 3 clinical trial that enrolls approximately 1,400 healthy individuals who have completed the primary and booster series of vaccination with a Covid-19 vaccine approved in Japan and evaluates the efficacy and safety of DS-5670 (Omicron-adapted bivalent vaccine) using a Covid19 vaccine (Omicron-adapted bivalent vaccine) approved in Japan as the control. Based on results from the booster vaccination trial, Daiichi Sankyo will pursue the approval of the Omicron adapted bivalent vaccine. Furthermore, the company will continuously work toward supplying mRNA vaccines against new variants of coronavirus. DS-5670 is an mRNA vaccine against Covid-19 using a novel nucleic acid delivery technology discovered by Daiichi Sankyo. It is designed to produce antibodies against the receptor binding domain (RBD) of the spike protein of the novel coronavirus and thus expected to have desirable prevention against Covid-19 and safety. Daiichi Sankyo aims to make it possible to distribute the mRNA vaccine at refrigeration temperatures (2-8?). The clinical development of DS-5670, including the mutant strain vaccine announced today, is being conducted through the

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!